The following is a summary of "Exploring the impact of metabolic comorbidities on epicardial adipose tissue in heart failure ...

Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing ...

BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) has become the most prevalent type of heart failure, but ...

A team of scientists led by Northwestern Medicine investigators have uncovered new details about a deadly heart condition ...

Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all heart failure cases, but has limited disease-modifying therapeutics. SRD-002 is a gene therapy utilizing an ...

An ejection fraction >35% is unconventional to be considered "preserved," so the results of this trial are inconclusive on whether patients with heart failure and ejection fractions usually ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with ...

In the new analysis of data from the SUMMIT trial, researchers focused on patients with obesity, chronic kidney disease and heart failure with preserved ejection fraction because they commonly have ...

Findings presented at the American College of Cardiology Annual Scientific Session indicate that finerenone's efficacy in ...